Adicet Bio
ACET
102 hedge funds and large institutions have $591M invested in Adicet Bio in 2022 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 44 increasing their positions, 20 reducing their positions, and 19 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 20
11% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 19
6% more capital invested
Capital invested by funds: $556M → $591M (+$34.9M)
1% more funds holding
Funds holding: 101 → 102 (+1)
0.55% more ownership
Funds ownership: 5.94% → 6.49% (+0.55%)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
45% less call options, than puts
Call options by funds: $2.29M | Put options by funds: $4.17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$32.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$23.5M |
| 3 |
RI
RTW Investments
New York
|
+$4.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.19M |
| 5 |
BlackRock
New York
|
+$4.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$7.25M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.35M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$5.56M |
| 4 |
Two Sigma Investments
New York
|
-$5M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$3.97M |
ACET Hedge Fund Activity: Q3 2022 in Review
102 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q3 2022, worth a combined $591M — up 6.3% from $556M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ACET positions and 19 closed out — a net gain of 2 holders — while 44 added to existing stakes and 20 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $32.7M. The largest seller was Assenagon Asset Management, cutting an estimated $7.25M.
- 102 institutional investors held Adicet Bio (ACET) as of Q3 2022, up from 101 in Q2 2022.
- Funds reported $591M of Adicet Bio stock for Q3 2022, up 6.3% quarter-over-quarter.
- 21 funds opened new Adicet Bio positions in Q3 2022 and 19 closed out, a net change of +2 holders.
- The largest Adicet Bio buyer in Q3 2022 was RA Capital Management, an estimated $32.7M added.
- The largest Adicet Bio seller in Q3 2022 was Assenagon Asset Management, an estimated $7.25M sold.
Based on aggregated 13F filings for Q3 2022.